Acorda's multiple sclerosis drug faces generic threat

June 26 Thu Jun 26, 2014 6:36am EDT

June 26 (Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.

Acorda said Actavis has submitted a marketing approval application with the U.S. Food and Drug Administration for a generic version of the drug.

Acorda said it intends to vigorously defend its intellectual property rights.

(Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
Mondoas wrote:
Well, this so call walking drug was suppose to help me walk better! This drug made me worse and the customer service there is horrible. They could never get their stories straight and they did not seem to care either. I had never YELLED on a phone like this until I dealt with this company and their crappy product!!!!!! Please remember, what happened to me happened to me so this product could do wonders for you!

Jun 27, 2014 6:15pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.